Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological...

Area of Science:

• Medicinal Chemistry
• Endocrinology
• Molecular Biology

Background:

• Estrogen receptor (ER) modulators are crucial for treating hormone-dependent diseases.
• Developing novel compounds with specific ER binding and activity profiles is an ongoing research area.

Purpose of the Study:

• To synthesize and characterize novel C2-alkyl substituted 1,1,2-tris(4-hydroxyphenyl)ethene derivatives.
• To evaluate their binding affinity to the estrogen receptor and their activity in ER-positive breast cancer cells.

Main Methods:

• Synthesis of C2-alkyl substituted 1,1,2-tris(4-hydroxyphenyl)ethenes via multi-step organic reactions.
• Estrogen receptor binding affinity assay using radio-labeled estradiol.
• Gene activation assays in ER-positive MCF-7-2a breast cancer cells to assess antagonistic and agonistic effects.

Main Results:

• All synthesized compounds exhibited high estrogen receptor binding affinity, with varying potency.
• The derivatives effectively antagonized estradiol's effect in MCF-7-2a cells, with compounds 3b and 3c showing potency comparable to 4-hydroxytamoxifen.
• Agonistic effects were generally low, although compounds 3a and 3b showed some luciferase expression activation.

Conclusions:

• C2-alkyl substituted 1,1,2-tris(4-hydroxyphenyl)ethenes are potent ER antagonists with high binding affinity.
• These compounds display low cytotoxicity, suggesting potential therapeutic applications in hormone-related conditions.
• The study provides valuable insights into structure-activity relationships for ER modulators.